Want to see JP:4883 full AI Analyst Report?
Modalis Therapeutics Corporation (4883) AI Stock Analysis
Modalis Therapeutics Corporation
(TSE/TYO:4883)
The stock scores at the lowest end of the range, driven by a complete lack of revenue, accelerating cash burn, and a persistent downtrend across all technical indicators. The debt-free balance sheet is the sole positive factor but is insufficient to offset the severe fundamental and market weaknesses. This is a high-risk, pre-commercial biotech with no near-term catalysts evident in the data.
Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.18B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.62M
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.45
- Revenue Growth
- ―
- EPS Growth
- -5.66%
- Country
- Japan
- Employees
- 17
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Modalis Therapeutics Corporation Business Overview & Revenue Model
Company Description
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic mod...
How the Company Makes Money
Modalis Therapeutics primarily seeks to generate revenue through the development and monetization of its drug discovery platform and pipeline. Potential revenue streams for a clinical-stage biotech of this type typically include (i) upfront payments,...
Modalis Therapeutics Corporation Financial Statement Overview
Summary
Pre-revenue biotech with no sales, widening net losses (Â¥2.15B), and deeply negative cash flows (Â¥2.12B burn). Debt-free balance sheet provides some cushion, but equity is eroding rapidly. Overall financial health is very weak, typical of high-risk development-stage companies.
Income Statement
15Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 40.50M | 1.10M |
| Gross Profit | 0 | 0 | 0 | -731.00K | -83.17M | 1.10M |
| EBITDA | -2.17B | -2.21B | -2.15B | -2.37B | -2.58B | -667.55M |
| Net Income | -2.05B | -2.15B | -1.32B | -2.39B | -2.70B | -738.96M |
Balance Sheet | ||||||
| Total Assets | 3.14B | 2.96B | 3.69B | 2.03B | 3.13B | 6.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.02B | 2.81B | 3.58B | 1.88B | 2.93B | 4.94B |
| Total Debt | 270.00M | 0 | 0 | 412.50M | 0 | 0 |
| Total Liabilities | 673.71M | 170.94M | 143.47M | 645.50M | 188.60M | 519.92M |
| Stockholders Equity | 2.46B | 2.79B | 3.55B | 1.38B | 2.94B | 5.55B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -2.12B | -1.43B | -2.29B | -2.09B | -854.58M |
| Operating Cash Flow | 0 | -2.12B | -1.43B | -2.25B | -1.90B | -747.47M |
| Investing Cash Flow | 0 | -2.57M | -188.00K | -39.70M | -185.72M | 171.56M |
| Financing Cash Flow | 0 | 1.35B | 3.04B | 1.22B | 63.68M | 72.63M |
Modalis Therapeutics Corporation Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4883, the sentiment is Negative. The current price of 27.00 is below the 20-day moving average (MA) of 29.50, below the 50-day MA of 32.04, and below the 200-day MA of 45.37, indicating a bearish trend. The MACD of -1.22 indicates Positive momentum. The RSI at 41.24 is Neutral, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4883.
Modalis Therapeutics Corporation Peers Comparison
Overall Rating
JP:457461Neutral
JP:459751.75Neutral
JP:489250Neutral
JP:453946.5Neutral
JP:458239Underperform- JP:488337Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4574 | 61Neutral | JPY 13.02B | 18.99 | ― | 1.27% | 13.30% | 66.38% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4597 | 52Neutral | JPY 7.37B | -8.11 | -53.67% | ― | 32.42% | 61.00% |
| JP:4892 | 50Neutral | JPY 5.64B | -6.87 | ― | ― | 364.72% | 18.43% |
| JP:4539 | 47Neutral | JPY 5.47B | -44.12 | ― | 3.30% | 0.31% | -194.72% |
| JP:4582 | 39Underperform | JPY 3.72B | -0.48 | ― | ― | -30.58% | 6.93% |
| JP:4883 | 37Underperform | JPY 3.18B | -1.17 | ― | ― | ― | -5.66% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4883 | Modalis Therapeutics Corporation | 28.00 | -47.00 | -62.67% | |
| JP:4597 | Solasia Pharma KK | 27.00 | -6.00 | -18.18% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1515.00 | 30.29 | 2.04% | |
| JP:4574 | Taiko Pharmaceutical Co., Ltd. | 260.00 | -15.00 | -5.45% | |
| JP:4582 | Symbio Pharmaceuticals Limited | 44.00 | -71.00 | -61.74% | |
| JP:4892 | Cyfuse Biomedical K.K. | 559.00 | -26.00 | -4.44% |
Modalis Therapeutics Corporation Corporate Events
Modalis Therapeutics Issues Further Corrections to Interim Financial Results
Modalis Therapeutics Corporation announced further corrections to its consolidated financial results for the six months ended June 30, 2026, under Japanese GAAP. The adjustments affect explanatory materials linked to second-quarter balance sheet, fin...
Modalis Revises Interim Results After R&D Expense Timing Error
Modalis Therapeutics Corporation reported consolidated financial results for the six months ended June 30, 2026, under Japanese GAAP, showing continued operating losses, negative ordinary income, and a basic loss per share, but maintaining a solid eq...
Modalis Corrects Presentation Errors in Mid-Year Financial Report Without Impacting Results
Modalis Therapeutics Corporation announced corrections to its Business and Financial report for the six months ended June 30, 2026, noting that certain descriptive elements in its financial presentation materials contained errors. The company clarifi...
Modalis Books FX Gains and R&D Refund as One-Off Income Boost
Modalis Therapeutics Corporation reported non-operating income and extraordinary income for the six months ended June 30, 2026, highlighting specific one-off financial gains. The company recorded 6 million yen in foreign exchange income as non-operat...
Modalis Issues English Reference Version of Q2 2026 Financial Report
Modalis Therapeutics released an English reference translation of its second-quarter 2026 business and financial report, dated August 10, 2026. The document is designated as a translation of the original Japanese report, with the company stating that...
Modalis Therapeutics Narrows Interim Loss but Withholds 2026 Outlook
Modalis Therapeutics reported an interim consolidated loss for the six months ended June 30, 2026, with operating income at minus ¥1,000 million and profit attributable to owners of the parent at minus ¥920 million, narrowing slightly from...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026